{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:38:55Z","timestamp":1793162335148,"version":"4.5.0"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Substance use disorders (SUDs) remain a major global health challenge with limited pharmacological treatment options and high relapse rates. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for type 2 diabetes and obesity, have recently gained attention for their potential effects on addictive behaviors. Preclinical and early clinical studies suggest that GLP-1RAs modulate mesolimbic dopaminergic signaling and attenuate reward-driven behaviors, positioning them as promising candidates for novel interventions in addiction medicine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic literature review in accordance with PRISMA 2020 guidelines, with protocol registration in PROSPERO (CRD42024571356). Searches were performed across PubMed, Embase, Web of Science, PsycINFO, and the Cochrane Library up to January 2025. Eligible studies included preclinical and clinical investigations examining GLP-1RAs in alcohol, nicotine, cocaine, and opioid use disorders. Data were extracted on study design, sample characteristics, interventions, and primary outcomes related to substance use behavior and neurobiological mechanisms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 41 studies were included, comprising 35 preclinical and six clinical investigations. Preclinical evidence consistently demonstrated that GLP-1RAs, including exendin-4, liraglutide, and semaglutide, reduced substance intake, relapse-like behaviors, and cue-induced drug seeking across multiple drug classes. These effects were linked to GLP-1R activation in brain reward circuits, including the nucleus accumbens, ventral tegmental area, and nucleus of the solitary tract. Clinical studies provided preliminary support, particularly for alcohol use disorder, with GLP-1RAs showing reductions in alcohol consumption and craving in several clinical trials. However, clinical findings remain heterogeneous and limited by small sample sizes and short study durations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This systematic review highlights GLP-1RAs as a promising therapeutic approach for SUDs, targeting the neurobiological pathways underlying both metabolic and reward regulation. While preclinical data are convincing, clinical evidence remains preliminary, underscoring the need for larger, well-designed randomized controlled trials. GLP-1RAs may represent a novel pharmacological strategy bridging metabolic and neuropsychiatric domains in addiction treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024571356<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1702448","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:17Z","timestamp":1767335357000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":21,"title":["The potential role of GLP-1 receptor agonists in substance use disorders \u2013 a systematic review"],"prefix":"10.3389","volume":"16","author":[{"given":"K. M.","family":"V\u00f6lker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. L. H.","family":"Prechtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Bormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/WNR.0000000000001071","article-title":"Accumbal ghrelin and glucagon-like peptide 1 signaling in alcohol reward in female rats","volume":"29","author":"Abtahi","year":"2018","journal-title":"Neuroreport"},{"key":"B2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1037\/pha0000620","article-title":"Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice","volume":"31","author":"Allingbjerg","year":"2023","journal-title":"Exp. Clin. Psychopharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"108614","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1180512","DOI":"10.3389\/fphar.2023.1180512","article-title":"Antismoking agents do not contribute synergistically to semaglutide\u2019s ability to reduce alcohol intake in rats","volume":"14","author":"Aran\u00e4s","year":"","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"104642","DOI":"10.1016\/j.ebiom.2023.104642","article-title":"Semaglutide reduces alcohol intake and relapse-like drinking in male and female rats","volume":"93","author":"Aran\u00e4s","year":"","journal-title":"eBioMedicine"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001527","article-title":"How treatment-refractory addiction is defined: a scoping review","author":"Bormann","year":"2025","journal-title":"J. Addict. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"ENEURO.0443","DOI":"10.1523\/ENEURO.0443-18.2019","article-title":"Glucagon-Like Peptide-1 receptor agonist treatment does not reduce abuse-related effects of opioid drugs","volume":"6","author":"Bornebusch","year":"2019","journal-title":"eNeuro"},{"key":"B8","doi-asserted-by":"publisher","first-page":"114249","DOI":"10.1016\/j.bbr.2022.114249","article-title":"Mesolimbic exendin-4 attenuates reward salience evoked by neuropeptide Y and ghrelin","volume":"440","author":"Brigande","year":"2023","journal-title":"Behav. Brain Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e170671","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"B10","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.3390\/ijms21249710","article-title":"Brain site-specific inhibitory effects of the GLP-1 analogue Exendin-4 on alcohol intake and operant responding for palatable food","volume":"21","author":"Colvin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"113726","DOI":"10.1016\/j.bbr.2021.113726","article-title":"Differential effects of intra-ventral tegmental area ghrelin and glucagon-like peptide-1 on the stimulatory action of D-amphetamine and cocaine-induced ethanol intake in male Sprague Dawley rats","volume":"421","author":"Colvin","year":"2022","journal-title":"Behav. Brain Res."},{"key":"B12","unstructured":"Better systematic review management\n          \n          \n          2016"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00213-023-06367-x","article-title":"Sex-dependent divergence in the effects of GLP-1 agonist exendin-4 on alcohol reinforcement and reinstatement in C57BL\/6J mice","volume":"240","author":"D\u00edaz-Megido","year":"2023","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1111\/acer.14437","article-title":"Glucagon-Like Peptide-1 receptor signaling in the ventral tegmental area reduces alcohol self-administration in Male rats","volume":"44","author":"Dixon","year":"2020","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/FBP.0000000000000609","article-title":"Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats","volume":"32","author":"Douton","year":"2021","journal-title":"Behav. Pharmacol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/FBP.0000000000000685","article-title":"Acute glucagon-like peptide-1 receptor agonist liraglutide prevents cue-stress-and drug-induced heroin-seeking in rats","volume":"33","author":"Douton","year":"","journal-title":"Behav. Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13117","DOI":"10.1111\/adb.13117","article-title":"Glucagon-like peptide-1 receptor agonist, liraglutide, reduces heroin self-administration and drug-induced reinstatement of heroin-seeking behaviour in rats","volume":"27","author":"Douton","year":"","journal-title":"Addict. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.brainresbull.2022.08.022","article-title":"Dose titration with the glucagon-like peptide-1 agonist, liraglutide, reduces cue- and drug-induced heroin seeking in high drug-taking rats","volume":"189","author":"Evans","year":"2022","journal-title":"Brain Res. Bull."},{"key":"B20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00213-024-06637-2","article-title":"Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys","volume":"242","author":"Fink-Jensen","year":"2024","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B54","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1001\/jamapsychiatry.2024.4789","article-title":"Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial","volume":"82","author":"Hendershot","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s00213-023-06376-w","article-title":"Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats","volume":"240","author":"Herman","year":"2023","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/adb.12583","article-title":"Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats","volume":"24","author":"Hernandez","year":"2019","journal-title":"Addict. Biol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1038\/s41380-020-00957-3","article-title":"GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA","volume":"26","author":"Hernandez","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"B26","article-title":"Eine praxisrelevante \u00dcbersicht","year":"2022"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"B28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"L\u00e4hteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101865","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"eClinicalMedicine"},{"key":"B30","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"L\u00fcthi","year":"2024","journal-title":"eClinicalMedicine"},{"key":"B31","doi-asserted-by":"publisher","first-page":"599646","DOI":"10.3389\/fnins.2020.599646","article-title":"Long-Acting glucagon-like Peptide-1 receptor agonists suppress voluntary alcohol intake in Male Wistar rats","volume":"14","author":"Marty","year":"2020","journal-title":"Front. Neurosci."},{"key":"B32","unstructured":"PRISMA statement\n          \n          \n          2018"},{"key":"B33","doi-asserted-by":"publisher","year":"2019","journal-title":"PRISMA Statement","DOI":"10.1136\/bmj.n71"},{"key":"B34","unstructured":"PRISMA statement\n          \n          \n          2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e170419","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"B36","unstructured":"2021"},{"key":"B37","unstructured":"A revised Cochrane risk-of-bias tool for randomized trials | Cochrane Bias\n          \n          \n          2023"},{"key":"B53","unstructured":"Risk of bias tools"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-Like Peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.physbeh.2016.04.013","article-title":"Central & peripheral glucagon-like peptide-1 receptor signaling differentially regulate addictive behaviors","volume":"161","author":"Sirohi","year":"2016","journal-title":"Physiol. Behav."},{"key":"B40","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.physbeh.2015.06.013","article-title":"The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice","volume":"149","author":"S\u00f8rensen","year":"2015","journal-title":"Physiol. Behav."},{"key":"B41","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1111\/acer.13199","article-title":"Effects of the GLP-1 agonist Exendin-4 on intravenous ethanol self-administration in mice","volume":"40","author":"S\u00f8rensen","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.pbb.2017.07.014","article-title":"The glucagon-like peptide 1 receptor agonist Exendin-4 decreases relapse-like drinking in socially housed mice","volume":"160","author":"Thomsen","year":"2017","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B44","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacol. (Berl.)"},{"key":"B45","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/nn.4540","article-title":"GLP-1 acts on habenular avoidance circuits to control nicotine intake","volume":"20","author":"Tuesta","year":"2017","journal-title":"Nat. Neurosci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.brainresbull.2022.08.023","article-title":"Acute treatment with the glucagon-like peptide-1 receptor agonist, liraglutide, reduces cue- and drug-induced fentanyl seeking in rats","volume":"189","author":"Urbanik","year":"2022","journal-title":"Brain Res. Bull."},{"key":"B47","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/adb.12295","article-title":"The glucagon-like peptide 1 receptor agonist liraglutide attenuates the reinforcing properties of alcohol in rodents","volume":"21","author":"Vall\u00f6f","year":"2016","journal-title":"Addict. Biol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.psyneuen.2019.02.006","article-title":"Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents","volume":"103","author":"Vall\u00f6f","year":"","journal-title":"Psychoneuroendocrinology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuropharm.2019.02.020","article-title":"Glucagon-like peptide-1 receptors within the nucleus of the solitary tract regulate alcohol-mediated behaviors in rodents","volume":"149","author":"Vall\u00f6f","year":"","journal-title":"Neuropharmacology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-00923-1","article-title":"Long-term treatment with a glucagon-like peptide-1 receptor agonist reduces ethanol intake in male and female rats","volume":"10","author":"Vall\u00f6f","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and May reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob. Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"769664","DOI":"10.3389\/fnbeh.2021.769664","article-title":"Effects of glucagon-like Peptide-1 receptor agonist Exendin-4 on the reinstatement of cocaine-mediated conditioned place preference in mice","volume":"15","author":"Zhu","year":"2022","journal-title":"Front. Behav. Neurosci."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1702448\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:17Z","timestamp":1767335357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1702448\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":53,"alternative-id":["10.3389\/fphar.2025.1702448"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1702448","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1702448"}}